Prior to publication, the information contained within this announcement was deemed by the Group to constitute inside information for the purposes of Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. With the publication of this announcement, this information is now considered to be in the public domain.
5 April 2024
NAHL Group PLC
("NAHL" or the "Group")
Response to speculation
The Board of NAHL (AIM: NAH), a leading UK marketing and services business focused on the UK consumer legal market, notes the recent speculation regarding the potential sale of its Critical Care business, Bush & Company Rehabilitation Limited ("Bush & Co").
The Board is pleased with the progress that Bush & Co has made in growing revenues and profitability and continues to believe that there is an exciting opportunity for that business in its market. However, the Board is always considering strategic options that seek to accelerate growth in value for shareholders and can confirm that it is currently investigating the potential sale of Bush & Co.
Whilst an adviser has been appointed in relation to a potential sale of Bush & Co, this matter is at a very early stage and there can be no certainty that a sale of Bush & Co will occur, nor as to the terms or timing of such sale. No discussions have taken place with any potential purchaser and no approach for the business has been received. Further announcements will be made as appropriate.
For further information:
| NAHL Group PLC James Saralis (CEO) Chris Higham (CFO)
| via FTI Consulting Tel: +44 (0) 20 3727 1000 |
| Allenby Capital (AIM Nominated Adviser & Broker) Jeremy Porter/Liz Kirchner (Corporate Finance) Amrit Nahal/Stefano Aquilino (Sales & Corporate Broking)
| Tel: +44 (0) 20 3328 5656 |
| FTI Consulting (Financial PR) Alex Beagley Eleanor Purdon Amy Goldup | Tel: +44 (0) 20 3727 1000 NAHL@fticonsulting.com |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.